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Abstract
Introduction: Subjective cognitive decline (SCD) may be an early symptomatic man-
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ifestation of Alzheimer’s disease, though published research largely neglects how to
classify SCD in community-based studies.
Methods: In neuropsychologically intact Einstein Aging Study participants (n = 1115;
mean age = 78; 63% female; 30% non-White), we used Cox models to examine the association between self-perceived cognitive functioning at baseline (using three different
approaches) and incident amnestic mild cognitive impairment (aMCI) with covariates
of age, sex, education, race/ethnicity, general (objective) cognition, depressive symptoms, and four other SCD-related features.
Results: After a median of 3 years, 198 participants developed aMCI. In models that
included all the variables, self-perceived cognitive functioning was consistently associated with incident aMCI as were age, general cognition, and perceived control;
apolipoprotein E (APOE) ε4 allele status was significant in one model. We set cut points
that optimized the diagnostic accuracy of SCD at various time frames.
Discussion: We provide an approach to SCD classification and discuss implications for
cognitive aging studies.
KEYWORDS

Alzheimer’s disease, classification, longitudinal study, memory complaints, mild cognitive impairment, subjective cognition, subjective cognitive decline, questionnaire

1

INTRODUCTION

early symptomatic expression of preclinical AD.1,3 Research on SCD*
most often focuses on establishing a relation of SCD to specific AD

Some older adults have persistent feelings that aspects of their mem-

biomarkers4–21 or to validating SCD as a risk condition for mild cog-

ory and thinking are becoming worse over time or worse compared to

nitive impairment (MCI), AD,21–27 or other diseases that may lead to

others their age.1 Consensus groups have sought to provide a com-

dementia,1,25 with comparatively little attention paid to measurement

mon construct for individuals who present with subjective cognitive
decline (SCD) in the context of intact performance on neuropsychological tests and preserved daily functioning and independence.1 The
condition of SCD is now recognized by some as a transitional stage in
the Alzheimer’s disease (AD) pathological continuum,2 and possibly an

* It is important to note that various terms may be used to capture the idea of SCD, such as [subjective] cognitive complaints, [subjective] memory complaints, [subjective] memory concerns,
subjective memory impairment, subjective cognitive impairment, and although we adopt the
concept of SCD introduced by the Subjective Cognitive Decline Initiative working group [SCD-

I] in 2014,1 studies referenced in this article do not exclusively use that concept or terminology.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer’s Association
Alzheimer’s Dement. 2020;12:e12103.
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issues including how to classify SCD in diverse research settings.28,29
Studies that treat SCD as a diagnostic group,4,8,14,17,19,20,22,26,30,31

RESEARCH IN CONTEXT

as opposed to a continuous variable,5,6,9,13,18,32 must determine a

1. Systematic review: Despite a proliferation of publica-

threshold for categorizing neuropsychologically intact individuals

tions on various aspects of subjective cognitive decline

as having significant self-perceived cognitive decline. The goal is to

(SCD), the critical issue of how to optimize classification,

distinguish between those whose concerns about cognition reach a

particularly in community-based studies, has received

threshold for significance that may be attributed to underlying neu-

almost no attention. The authors carried out an extensive

rodegenerative changes consistent with prodromal AD1,28 (or other

PubMed search for literature on approaches to classifica-

dementia subtypes) from those whose concerns are generally mild

tion of SCD in neuropsychologically intact older adults.

and attributed to benign conditions associated with normal aging.33

2. Interpretation: We showed that subjective cognitive

Thus, the distinction between SCD and cognitively normal (CN) is

function scores (and relevant covariates) were associated

made on the basis of subjective cognitive report data, as both groups

with incident amnestic mild cognitive impairment (aMCI)

by definition are unimpaired on standardized objective neurocognitive

and could be used to classify SCD in a manner that opti-

tests.

mizes the early detection of aMCI.

To enable comparison of findings across studies it is important to

3. Future directions: Future research should investigate

establish, refine, and consistently apply SCD classification criteria.29

whether the current classification approach can be

However, there is no gold standard instrument or sufficiently val-

applied successfully in other studies and whether it pro-

idated cut points on measures of self-perceived cognitive func-

duces a diagnosis that is stable and predicts important

tioning for differentiation between CN participants and those with

clinical and cognitive outcomes. In addition, alternative

SCD.28 Moreover, there is almost no consistency in how SCD is

methods should be developed and compared, and at a

operationalized in studies that use community- or population-based

minimum all future research on SCD should report the

recruitment methods.† Many researchers classify SCD based on a

specific classification approach and rationale for its use.

positive response to a single question about perceived difficulty,
change, or worry/concern about one’s memory or cognition,14,20,30,31
while others use cut scores/median split approaches,26,36 or other
methods.4,8,17,19,37 Notably, the rationale or justification for the
selected classification approach for SCD is rarely provided.

nition used was consistent and had significant overlap with the criteria

When deciding how to classify SCD in research settings, it is instruc-

for clinical cognitive staging in the absence of biomarkers, put forth

tive to consider features thought to increase the likelihood of preclin-

by the National Institute on Aging-Alzheimer’s Association Research

ical AD in those with SCD (ie, sometimes referred to as “SCD-plus”).1

Framework.2 Next, we determined whether the four available SCD-

These include: subjective decline specific to memory, onset of SCD

plus (and other related) features added to the predictive ability. Finally,

within the last 5 years, age at onset of SCD ≥ 60 years, expression

using information derived from the predictive models, we evaluated

of concerns (worries) associated with SCD, feeling of worse cognitive

the discriminative ability of self-perceived cognitive functioning (alone

performance compared to others of the same age group, confirmation

and in combination with other variables) for incident aMCI after

of cognitive decline by an informant, presence of the apolipoprotein E

various follow-up periods from baseline to determine optimal cut

(APOE) ε4 allele, and biomarker evidence of AD. The SCD-plus concept,

scores for defining SCD.

which is subject to ongoing expansion, refinement, and validation,33
may be a low-cost enrichment strategy for preclinical AD in secondary

2

prevention trials.38

METHODS

In the current study, we established a method for classifying SCD in
participants from the Einstein Aging Study (EAS) who were neuropsy-

2.1

Participants

chologically intact at baseline. Our classification approach optimized
predictive validity for incident amnestic MCI (aMCI), often thought to

Participants were drawn from the EAS, a longitudinal community-

be a precursor of AD.39

In participants who were neuropsychologically

based study that includes a demographically diverse cohort from the

intact at baseline, we examined the association of self-perceived

Bronx, NY. As described elsewhere,40 participants were recruited

cognitive functioning, as described in the Methods section, with the

through systematic sampling from Medicare or voter registration

incidence of aMCI, controlling for relevant covariates. The aMCI defi-

lists. Individuals were mailed introductory letters and then screened
by telephone. Those who met preliminary eligibility criteria were

† For clinical/help-seeking SCD samples, which recruit from memory clinics and/or local physi-

cians, there is greater consistency in approach, with SCD typically defined by spontaneous
expression of cognitive concerns by patients and/or informants, or by virtue of having been
referred for cognitive evaluation in the first place.10,12,15,16,34,35 Notably, individuals with
SCD from memory clinics settings may be at greater risk for progressive cognitive decline than
those from community settings.25,26,37

invited for further in-person screening. Participants were aged 70
years or older, non-institutionalized, ambulatory, and English speaking.
Exclusion criteria included severe audiovisual or physical impairments
or active psychiatric symptomatology, which interfered with the
ability to complete assessments. The study was approved by the
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local institutional review board and participants provided written

in memory compared to 1 and 10 years prior to the assessment

informed consent at baseline assessment. In-person assessments

(ordinal data with 3 to 4 response options); and one dichotomous

were conducted annually and included neurological and neuropsy-

item from the short form of the Geriatric Depression Scale (GDS),51

chological examinations, and ascertainment of demographics, medical

which inquires whether participants feel they have “more memory

history, activities of daily living, and self-perceived cognitive func-

problems than most.” The EAS also includes items that assess infor-

tioning. Informant reports regarding cognition and function were

mant perceptions of participants’ cognition: 21 items from the CERAD

available for ≈51% of participants. APOE ε4 allele status was available

(informant form), a yes/no/don’t know rating scale of current cognitive

for 48% of participants. Participants eligible for this analysis were

functioning.

enrolled between October 1993 and June 2016; were free of all MCI,

Responses to items probing self-perceived cognitive functioning

AD, and other dementias at baseline; and had at least one annual

were recoded, as needed, such that higher values consistently indi-

follow-up.

cated greater level of cognitive concern/impairment. Table 1 presents
the items, their respective cognitive domains, and scoring.‡ A subjective
cognitive function score defined as the sum of responses to all 22 items

2.2
Neuropsychological assessment and
participant classification

tapping self-perceived cognitive functioning was used as the primary
summary measure of SCD (possible range: 2 to 28). An adjusted subjective cognitive function score that excluded the five items used for aMCI

Participants underwent neuropsychological testing at baseline and

diagnosis was used as an alternative summary measure of SCD (pos-

follow-up visits.40 The battery included the picture version of the Free

sible range: 2 to 23). Where applicable, don’t know response options,

(FCSRT);41

which were infrequent (ie, <5% and 8% of responses for self- and infor-

the Wechsler Memory Scale-Revised Logical Memory I subtest (WMS-

mant items, respectively), were handled as missing data. Approximately

R-LMI);42 Trail-Making Test Parts A and B;43 Digit Symbol, Block

35% of participants did not have complete data for all the subjective

Design, and Digit Span subtests of the Wechsler Adult Intelligence

cognitive function items (see note in Table 2).

and Cued Selective Reminding Test with Immediate Recall

Scale—Revised;44

F-A-S Letter Fluency

Test;45

Boston Naming

Test;46

and Category Fluency.47 Data derived from these tests were used to
classify participants as aMCI, non-aMCI (naMCI), and dementia.

2.4

Covariates

Dementia diagnoses were assigned at a consensus case conference
attended by a neurologist and neuropsychologist applying Diagnos-

Covariates were selected based on previously reported associations

tic and Statistical Manual of Mental Disorders Fourth Edition Text

with SCD.28,29 Sociodemographic variables included age (years; contin-

criteria.48

aMCI diagnoses were assigned to

uous), sex (male, female; dichotomous), educational attainment (years;

non-demented participants who presented with objective memory

continuous), and ethnicity (White; Black; other; categorical). Depres-

impairment as measured by a score of less than or equal to 24 on

sive symptoms were assessed with the 15-item self-report GDS, using

free recall (possible range: 0 to 48) from the FCSRT or 1.5 or greater

an adjusted score that did not include the one cognitive item. A co-

standard deviations below age-corrected normative mean scores on

morbidity illness scale was the sum (range 0 to 10) of the number of

WMS-R-LMI. Additionally, participants were required to endorse at

self-reports of arthritis, angina, depression, diabetes, chronic obstruc-

least one item from among specific Consortium to Establish a Registry

tive pulmonary disease, hypertension, myocardial infarcts, heart fail-

for Alzheimer’s Disease (CERAD) clinical history self-reported memory

ure, Parkinson’s disease, and stroke.53 The Blessed Information-

items (Table 1) or one item from among specific informant reported

Memory-Concentration Test (BIMC, possible range: 0 to 33), was not

memory items (Table 1), and have no functional impairment on the

used to classify aMCI, but we did adjust for it in models assessing aMCI

Lawton Brody Instrumental Activities of Daily Living scale. The aMCI

as an outcome; higher scores indicated worse general cognitive status.

Revision (DSM-IV-TR)

group included both single (memory impairment only) and multiple
domain (deficits in memory and at least one additional cognitive
domain) subtypes. We did not include participants with non-amnestic

2.5

Additional variables of interest

subtypes of MCI at baseline. CN did not meet criteria for dementia or
any MCI subtype.

For selected study analyses, we also included data related to SCD-plus
criteria. The four SCD-plus features assessed were APOE ε4 allele status (dichotomized as ε4-carrier or ε4-non carrier), informant report of

2.3

Self-perceived cognitive functioning

cognitive function (subjective cognitive function informant score based on
the sum of CERAD binary items, possible range: 0 to 21 or 0 to 16

We used 22 items derived from three questionnaires administered at
each visit (Table 1): 17 items from the CERAD clinical history question-

‡ Cognitive domains were previously assigned as part of a descriptive analysis of 640 cognitive

naire; a yes/no/don’t know rating scale of current functioning in several

self-report items that included the EAS measures/items.52 For each item, we designated a primary cognitive domain from one of the following: memory; attention/working memory/processing
speed; language; executive function; basic calculation and arithmetic; orientation; general cognitive
ability; and visuospatial skills.

cognitive domains;49 four items from the EAS Health Self-Assessment
(HSA)50 that inquire about current memory problems and changes
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TA B L E 1

Items and response options probing self- and informant-perceived cognitive functioning

Measure and source

Cognitive domain

Item stem

Response options/(score)

CERAD, self-1

a

Memory

Do you have difficulty remembering things that happened
recently?

Yes (1)/No (0)/Don’t Know

CERAD, self-2

a

Memory

Do you forget conversations that occurred a few days or
hours earlier?

Yes (1)/No (0)/Don’t Know

CERAD, self-3

a

Memory

Do you seem to ask the same questions repeatedly?

Yes (1)/No (0)/Don’t Know

CERAD, self-4

a

Memory

Do you forget to turn off the stove?

Yes (1)/No (0)/Don’t Know

CERAD, self-5

Memory

Do you forget approaching holidays, days to attend religious
services, income tax dates, etc.?

Yes (1)/No (0)/Don’t Know

CERAD, self-6

Memory

Do you have trouble remembering short lists for shopping,
etc.?

Yes (1)/No (0)/Don’t Know

CERAD, self-7

Language

Do you have trouble finding words in carrying on a
conversation?

Yes (1)/No (0)/Don’t Know

CERAD, self-8

Language

Is it sometimes difficult for others to understand what you
are talking about?

Yes (1)/No (0)/Don’t Know

CERAD, self-9

Language

Do you have difficulties relating to or understanding T.V.
shows or newspaper articles?

Yes (1)/No (0)/Don’t Know

CERAD, self-10

Visuospatial

Do you have trouble finding the bedroom or bathroom at
home or in other familiar houses (friends or relatives)?

Yes (1)/No (0)/Don’t Know

CERAD, self-11

Visuospatial

Do you get lost in familiar surroundings, such as local
neighborhood or shopping malls?

Yes (1)/No (0)/Don’t Know

CERAD, self-12

Calculation

Do you have difficulty handling small sums of money?

Yes (1)/No (0)/Don’t Know

CERAD, self-13

Orientation

Do you have trouble remembering the day or the month?

Yes (1)/No (0)/Don’t Know

CERAD, self-14

Executive function

Do you have difficulty operating simple household
appliances (eg, T.V., lawnmower or vacuum cleaner)?

Yes (1)/No (0)/Don’t Know

CERAD, self-15

Executive function

Do you have difficulty performing simple household tasks
(eg, making a cup of coffee, setting the table)?

Yes (1)/No (0)/Don’t Know

CERAD, self-16

Executive function

Do you show problems in judgement such as responding
inappropriately to a salesman at the door?

Yes (1)/No (0)/Don’t Know

CERAD, self-17

General cognitive
ability

Do you have any other cognitive problems?

Yes (1)/No (0)/Don’t Know

HSA, self-1

Memory

In the past year, how often did you have trouble
remembering things?

Frequently (3)/Sometimes (2)/Rarely
(1)/Never (0)

HSA, self-2

Memory

Compared to 1 year ago, do you have trouble remembering
things?

More often (3)/Less Often (1)/About
the Same (2)

HSA, self-3

Memory

Compared to 10 years ago, do you have trouble
remembering things?

More often (3)/Less Often (1)/About
the Same (2)

HSA, self-4

Memory

Has your memory change caused any serious problems (eg,
forgetting to turn off the stove, getting lost, misplacing
valuables)?

Yes (1)/No (0)/Don’t Know

Memory

Do you feel that you have more problems with memory than
most?

Yes (1)/No (0)

a

GDS, self

CERAD, informant-1

a

Memory

Does he/she have difficulty remembering things that
happened recently?

Yes (1)/No (0)/Don’t Know

CERAD, informant-2

a

Memory

Does he/she forget conversations that occurred a few days
or hours earlier?

Yes (1)/No (0)/Don’t Know

a

Memory

Does he/she seem to ask the same questions repeatedly?

Yes (1)/No (0)/Don’t Know

a

Memory

Does he/she forget to turn off the stove?

Yes (1)/No (0)/Don’t Know

CERAD, informant-5

Memory

Does he/she forget approaching holidays, days to attend
religious services, income tax dates, etc.?

Yes (1)/No (0)/Don’t Know

CERAD, informant-6

Memory

Does he/she have difficulty remembering short lists for
shopping, etc.?

Yes (1)/No (0)/Don’t Know

CERAD, informant-3
CERAD, informant-4

(Continues)
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TA B L E 1

(Continued)

Measure and source

Cognitive domain

Item stem

Response options/(score)

Memory

Do you believe he/she has a problem with memory?

Yes (1)/No (0)/Don’t Know

CERAD, informant-8

Language

Does he/she have trouble finding words in carrying on a
normal conversation?

Yes (1)/No (0)/Don’t Know

CERAD, informant-9

Language

Is it sometimes difficult for others to understand what he/she
is talking about?

Yes (1)/No (0)/Don’t Know

CERAD, informant-10

Language

Does he/she have difficulties relating to or understanding T.V.
shows or newspaper articles?

Yes (1)/No (0)/Don’t Know

CERAD, informant-11

Language

Do you believe he/she has a problem with language?

Yes (1)/No (0)/Don’t Know

CERAD, informant-12

Visuospatial

Does he/she have trouble finding the bedroom or bathroom
at home or in other familiar houses (friends or relatives)?

Yes (1)/No (0)/Don’t Know

CERAD, informant-13

Visuospatial

Does he/she get lost in familiar surroundings, such as local
neighborhood or shopping malls?

Yes (1)/No (0)/Don’t Know

CERAD, informant-14

Orientation

Does he/she have trouble remembering the day or the
month?

Yes (1)/No (0)/Don’t Know

CERAD, informant-15

Orientation

Do you believe he/she is disoriented for time or place?

Yes (1)/No (0)/Don’t Know

CERAD, informant-7

a

CERAD, informant-16

Calculation

Does he/she have difficulty handling small sums of money?

Yes (1)/No (0)/Don’t Know

CERAD, informant-17

Executive function

Does he/she have difficulty operating simple household
appliances (eg, T.V., lawnmower or vacuum cleaner)?

Yes (1)/No (0)/Don’t Know

CERAD, informant-18

Executive function

Does he/she have difficulty performing simple household
tasks (eg, making a cup of coffee, setting the table)?

Yes (1)/No (0)/Don’t Know

CERAD, informant-19

Executive function

Does he/she show problems in judgement such as
responding inappropriately to a salesman at the door?

Yes (1)/No (0)/Don’t Know

CERAD, informant-20

Executive function

Do you believe he/she has problems with judgement or
problem solving?

Yes (1)/No (0)/Don’t Know

CERAD, informant-21

General cognitive
ability

Does he/she have any other cognitive problems?

Yes (1)/No (0)/Don’t Know

Abbreviations: CERAD, Consortium to Establish a Registry for Alzheimer’s Disease clinical history; HSA, Einstein Aging Study Health Self-Assessment; GDS,
Geriatric Depression Scale, short form.
a
Denotes an item not used for the adjusted self- or informant subjective cognitive function scores.

for the adjusted subjective cognitive function informant score), and one

examine associations between the subjective cognitive function score

HSA item that taps into worry over health (ie, Has your overall health

and other variables of interest on risk of incident aMCI. Participants

caused you a great deal of worry/some worry/hardly any worry/or no

who developed dementia without developing aMCI were censored at

worry at all?). Although this item does not inquire specifically about

their time of dementia diagnosis. The proportional hazards assump-

worry related to cognition, we felt it captured something similar to

tions were examined using methods based on scaled Schoenfeld resid-

the SCD-plus criterion of concerns (worries) associated with SCD, in

uals and were satisfied.55 Time-dependent receiver operating charac-

the context of this cognitive aging study. We also included a related

teristic (ROC) analyses56,57 using the inverse probability of censoring

item from the HSA (ie, How much control do you think you have over

approach58 were used to examine the discriminative ability of subjec-

your future health?; great deal/some/very little/none at all), in light of

tive cognitive function score and other variables on incidence of aMCI

research showing associations between perceived control and various

within specified time periods. With the exception of the CERAD and

aspects of physical, emotional, and cognitive well-being, particularly in

GDS items noted in Table 1, the self- and informant subjective cogni-

older age.54

tive items used in our analyses were independent from those considered when diagnosing aMCI.
To deal with missing data for self- and informant subjective cogni-

2.6

Data analysis

tive items (including “don’t know” responses discussed above), APOE
ε4 allele status, and GDS, we applied the multiple imputation (MI)

Baseline characteristics were summarized with descriptive statistics

approach,59 which consists of imputation, analysis, and pooling. MI

for the whole sample and stratified by aMCI status at follow-up, and

uses all available data, thus increasing statistical power and prevent-

compared using chi-square tests, t-tests, or nonparametric Wilcoxon

ing bias. By comparison, the commonly used convenient method of

test if appropriate. Cox proportional hazards models were used to

complete case analysis, in which records with missing data are simply

6 of 13
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Baseline descriptive characteristics of whole sample and amnestic mild cognitive impairment (aMCI) status at follow-up
Whole sample

no aMCI

aMCI

Mean (SD) or percentage

n = 1115

n = 917

n = 198

Pa

Age, years at baseline

78.33 (5.17)

78.02 (5.08)

79.80 (5.34)

<.0001

Education (years)

13.79 (3.46)

13.81 (3.49)

13.70 (3.37)

.527

Sex, % female

63%

63%

61%

.485
.833

Ethnicity: % White

70%

69%

69%

% Black

25%

25%

26%

% Other

5%

6%

5%

Adjusted GDS score (max = 14)

2.05 (2.14)

2.03 (2.13)

2.17 (2.18)

.329

APOE ε4 allele status, carrier

21%b

20%

37%

.092

Medical index (max = 10)

1.82 (1.23)

1.83 (1.23)

1.78 (1.25)

.566

BIMC score (max = 33)

2.07 (2.03)

1.98 (2.01)

2.49 (2.09)

.0002

7.11 (2.01)

c

7.00 (1.96)

7.80 (2.13)

<.0001

1.06 (1.72)

d

0.95 (1.61)

1.61 (2.11)

.001

Subjective cognitive function score (max = 28)
Subjective cognition function informant score
(max = 21)

a

Note: Sample sizes before imputation: a n = 921; b n = 693; c n = 726; d n = 475.
Highlighted rows indicate statistically significant variables; this applies to subsequent tables.
Abbreviations: APOE, apolipoprotein E; BIMC, Blessed Information-Memory-Concentration test; GDS, Geriatric Depression Scale, short form; SD, standard
deviation.

deleted, is based on the stronger assumption that data are missing

score (described above). The adjusted subjective cognitive function

completely at random (MCAR) and is less efficient due to loss of infor-

score was examined in association with aMCI, adjusting for covariates

mation. For imputation, we adopted the fully conditional specification,

(Model 3a); we then further added available SCD-plus and related fea-

also known as imputation by chained equation method, to impute the

tures, including the adjusted subjective cognitive function informant

missing data using logistic regression models for binary and categorical

score.

variables, and linear regression models for continuous variables. All

Time-dependent ROC analysis was performed and area under the

variables used in the primary models were included in the imputation.

ROC curve (AUC) for developing aMCI within specified time periods

The fully conditional specification method is flexible and can handle

(3, 5, 7 years) were reported. The optimal cut points for SCD score and

mixed continuous and categorical variables with an arbitrary missing

for the combination of SCD and covariates were determined based on

data pattern. This step is repeated M times to generate M complete

the Youden index. Study analyses were carried out using SAS 9.4 (https:

data sets. For analysis, we performed the aforementioned analyses

//www.sas.com/en_us/software/sas9.html) and R,60 with an α value of

using Cox models and time-dependent ROC analyses for each of the

0.05 used to determine statistical significance.

M complete data sets. In the pooling step, the M sets of parameter
estimates were combined to appropriately reflect the uncertainty
associated with the imputed values. We set M = 20.

3

RESULTS

In our primary analysis, we used the subjective cognitive function
score as the primary measure. The association of this score with risk

3.1

Sample characteristics

of aMCI was evaluated using Cox models, adjusting for covariates
(Model 1a); we then added SCD-plus (and related) variables (Model

Our final sample included 1115 participants. At baseline (Table 2), par-

1b) to evaluate whether these variables further contributed to risk

ticipant age ranged from 70 to 97 (mean = 78.3 ± 5.2) years, the sam-

of aMCI and whether the association of SCD with aMCI persisted

ple was 62.8% female, and participants averaged 13.8 ± 3.5 years of

in presence of these variables. In a second approach, we examined

education. Subjective cognitive function score ranged from 3 to 19

all 22 items probing self-perceived cognitive functioning separately,

(mean = 7.1 ± 2.0). The sample was 70% White, 25% Black, and 5%

in association with aMCI, adjusting for covariates (Table 1). Items

other. A total of 198 participants developed aMCI during a median of

that were significantly associated with aMCI were then simultane-

3 years of follow-up (Q1 = 1.9, Q3 = 6.2, maximum 20). Those who

ously evaluated in a Cox model adjusting for covariates (Model 2a),

developed aMCI were significantly older at baseline (by ≈ 1 year), had

and then further adjusted for SCD-plus and related features (Model

higher BIMC scores (approximately half a point), and their informants

2b). To evaluate the impact of the potential circularity in the subjec-

endorsed a greater level of perceived cognitive decline. The groups did

tive cognitive function score caused by items used for aMCI diagno-

not differ by sex, education, race/ethnicity, depressive symptoms, med-

sis, we replaced the total score based on 22 items with the adjusted

ical index, or APOE ε4 allele status.
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TA B L E 3 Cox proportional hazard models assessing subjective cognitive function score on incident aMCI (adjusting for covariates) and with
SCD-plus variables
Model 1a
Variable

Hazard ratio

Model 1b
95% C.I.

P

Hazard ratio

95% C.I.

P

Baseline age (years)

1.10

1.07-1.13

<.0001

1.10

1.07-1.13

<.0001

Education (years)

1.01

0.97-1.06

.5990

1.01

0.97-1.06

.5889

Female

0.81

0.60-1.09

.1631

0.80

0.58-1.09

.1501

Race-Black

0.98

0.69-1.38

.8877

0.99

0.70-1.41

.9586

Race-other

0.90

0.45-1.80

.7658

0.88

0.44-1.76

.7116

Adjusted GDS score

1.03

0.95-1.11

.4876

1.02

0.94-1.10

.6994

Medical index

1.02

0.89-1.16

.7854

0.90

0.90-1.17

.7291

BIMC score

1.16

1.08-1.25

<.0001

1.15

1.07-1.24

.0002

Subjective cognitive function
score (1-point increase)

1.14

1.07-1.21

<.0001

1.11

1.04-1.19

.0039

Subjective cognitive function
informant score

1.10

0.98-1.25

.1167

APOE ε4 allele status

1.50

0.99-2.29

.0559

HSA worry

0.95

0.79-1.13

.5343

HSA control

1.25

1.04-1.50

.0159

Note: For the race covariate, non-Hispanic White was the reference group.
Abbreviations: aMCI, amnestic mild cognitive impairment; APOE, apolipoprotein E; BIMC, Blessed Information-Memory-Concentration test; HSA, Einstein
Aging Study Health Self-Assessment; SCD, subjective cognitive decline.

3.2
Effect of subjective cognition on incident
aMCI

over future health showed a significant effect, and APOE ε4 allele
status showed a marginally significant effect. As shown in Table 5
(Models 3a, 3b), when we examined subjective cognitive function

Table 3 (Model 1a) revealed that age, BIMC score, and subjective

using adjusted scores, the pattern of findings was similar; however,

cognitive function score all had significant effects, with a 1-point

in this model APOE ε4 allele status reached statistical significance,

increase in subjective cognitive function score increasing the risk

P = .0214.

of incident aMCI by 14% (P < .0001). We also reran Model 1a on
the subset of 720 participants with complete subjective cognitive
function data (105 incident aMCI cases), with the same pattern of

3.3

Diagnostic accuracy of SCD for incident aMCI

results (Table S1 in supporting information). We fit additional models
to account for the four SCD-plus and related features. In Model 1b, the

Given the combined results of earlier models, we focused on the

association of subjective cognitive function score with incident aMCI

subjective cognitive function score only, and the AUCs obtained from

persisted (hazard ratio [HR] = 1.11, P = .0039), as did higher BIMC

time-dependent ROC analysis for cumulative aMCI status. AUCs were:

score (P = .0002); control over future health also showed a significant

0.62 (standard error [SE] = 0.03, confidence interval [CI]: 0.56 to

effect (HR = 1.25 per one level of lower perceived control, P = .0159),

0.68) at 3 years, 0.60 (SE = 0.05, CI: 0.59 to 0.80) at 5 years, and 0.61

and APOE ε4 allele positive status showed increased risk but marginal

(SE = 0.03, CI: 0.55 to 0.68) at 7 years. The optimal cut-off values C for

significance (HR = 1.50, P = .056).

subjective cognitive function score based on Youden’s index, in which

Table S2 in supporting information displays the 22 items and their

values greater than C are considered positive, were 6, 6, and 7 at 3, 5,

individual associations with incident aMCI after adjusting for covari-

and 7 years, with sensitivities of 0.57, 0.55, and 0.47, and specificities

ates, with six memory items showing statistical significance (see high-

of 0.66, 0.61, and 0.71, respectively. Optimal cuts for the combination

lighted rows). Table S3 in supporting information displays baseline

of the subjective cognitive function score and covariates and SCD-plus

descriptive characteristics for variables used in Models 2 and 3. Table 4

features, as well as in combination with age (as the only significant

(Model 2a) revealed similar findings to Model 1a–with age, BIMC score,

covariate from these models), are reported in the supporting informa-

and one individual subjective memory item (HSA self-1: “In the past

tion. Kaplan Meier survival curves for SCD and CN groups (defined

year, how often did you have trouble remembering things?”) having

by subjective cognitive function score <= 6 and >6) from observed

significant effects. In Model 2b, the association of the one memory

data are presented in Figure 1. Risk of aMCI was more than doubled

item continued to be significant, as did age and BIMC score; control

(HR = 2.22, CI: 1.54 to 3.19, P < .0001) among SCD versus CN.
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TA B L E 4 Cox proportional hazard models assessing individual subjective cognitive function items on incident aMCI (adjusting for covariates)
and with SCD-plus variables
Model 2a
Variable

Hazard ratio

Model 2b
95% CI

P

Hazard ratio

95% CI

P

Baseline age (years)

1.10

1.07–1.13

<.0001

1.10

1.07-1.13

<.0001

Education (years)

1.01

0.97–1.05

.7015

1.01

0.97-1.06

.6432

Female

0.80

0.59–1.09

.1525

0.80

0.58-1.10

.1649

Race-Black

1.01

0.72–1.44

.9408

1.03

0.72-1.47

.8904

Race-Other

0.90

0.45–1.81

.7707

0.89

0.44-1.80

.7542

Adjusted GDS score

1.03

0.95–1.11

.5447

1.02

0.93-1.10

.7274

Medical index

1.02

0.89–1.16

.8246

1.02

0.89-1.16

.8187

BIMC score

1.15

1.07–1.23

.0001

1.14

1.06-1.23

.0008

CERAD, self-1

1.20

0.74–1.94

.4620

1.21

0.74-1.97

.4521

CERAD, self-6

1.36

0.84–2.21

.2167

1.16

0.68-1.98

.5976

HSA, self-1

1.47

1.10–1.98

.0107

1.42

1.05-1.91

.0212

HSA, self-3

1.29

0.93–1.79

.1277

1.27

0.92-1.76

.1488

HSA, self-4

1.23

0.81–1.86

.3320

1.31

0.86-1.98

.2103

GDS, self

1.43

0.86–2.38

0.1736

1.39

0.82-2.38

.2233

Subjective cognitive function
informant score

1.10

0.96-1.24

.1905

APOE ε4 allele status

1.45

0.949-2.24

.0942

HSA worry

0.91

0.77-1.10

.5343

HSA control

1.26

1.05-1.50

.0159

Note: For the race covariate, non-Hispanic White was the reference group.
Abbreviations: aMCI, amnestic mild cognitive impairment; APOE, apolipoprotein E; BIMC, Blessed Information-Memory-Concentration test; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease clinical history; CI, confidence interval; GDS, Geriatric Depression Scale, short form; HSA, Einstein
Aging Study Health Self-Assessment; SCD, subjective cognitive decline.

TA B L E 5 Cox proportional hazard models assessing adjusted subjective cognitive function score on incident aMCI (adjusting for covariates)
and with SCD-plus variables
Model 3a

Model 3b

Variable

Hazard ratio

95% CI

P

Hazard ratio

95% CI

P

Baseline age (years)

1.09

1.07–1.13

<.0001

1.10

1.07–1.13

<.0001

Education (years)

1.01

0.97–1.06

.5253

1.01

0.97–1.06

.5232

Female

0.81

0.60–1.09

.1698

0.79

0.58–1.08

.1418

Race-Black

0.98

0.69–1.39

.9061

0.98

0.68–1.40

.8938

Race-other

0.88

0.44–1.76

.7181

0.85

0.42–1.72

.6539

Adjusted GDS score

1.03

0.95–1.10

.4908

1.01

0.94–1.10

.7457

Medical index

1.03

0.91–1.18

.6419

1.03

0.90–1.18

.06755

BIMC score

1.16

1.08–1.25

<.0001

1.15

1.07–1.23

.0002

Adjusted subjective cognitive function
score (1-point increase)

1.19

1.08–1.30

<.0004

1.16

1.06–1.27

.0014

Adjusted subjective cognitive function
informant score

1.16

0.96–1.41

.1210

APOE ε4 allele status

1.59

1.07–2.37

.0214

HSA worry

0.96

0.81–1.14

.6538

HSA control

1.22

1.03–1.45

.0233

Note: For the race covariate, non-Hispanic White was the reference group.
Abbreviations: aMCI, amnestic mild cognitive impairment; APOE, apolipoprotein E; BIMC, Blessed Information-Memory-Concentration test; CI, confidence
interval; GDS, Geriatric Depression Scale, short form; HSA, Einstein Aging Study Health Self-Assessment; SCD, subjective cognitive decline.

9 of 13

RABIN ET AL .

the six items with statistically significant associations with aMCI all
related to memory (Table S1). This offers support for the idea that selfperceived decline in memory, rather than in other cognitive domains,
may increase the likelihood of preclinical AD in those with SCD (an
SCD-plus feature). When additional variables were added, one memory
item continued to show statistical significance (HSA, self-1, Table 1).
This item, which inquired about trouble remembering things in the past
year, was previously found to be among the most commonly used selfreport items in cognitive aging studies,52 and likely merits inclusion in
future assessments.
Most of the other SCD plus features that we had available did
not make a statistically significant impact on the incidence of aMCI.
Specifically, subjective cognitive function informant score, worry about
health, and perception of worse memory than others, were not significant. The GDS item that asks whether an individual feels he/she has
“more problems with memory than most” was associated with aMCI in
the model that only adjusted for demographics—but did not retain sigF I G U R E 1 Kaplan-Meier survival curve by subjective cognitive
function score (cut score 6) obtained from the observed data (n = 726)

nificance in the full model. This item, though widely used in the field,
has mixed support for its utility—and may be more valid for capturing
self-perceived memory difficulty in those with MCI than in cognitively
unimpaired older adults.61 APOE ε4 allele status showed marginal or

4

statistical significance in all models. As APOE ε4 is an important genetic

DISCUSSION

risk factor for AD, and may be associated with the prospective risk
The field of cognitive aging is focused on earlier, and more efficient,

of cognitive decline in SCD,62–64 it may be worth incorporating APOE

identification of individuals free of objective cognitive impairment who

data into SCD classification. However, it is notable that our approach

are most at-risk for future decline. Self-perceived cognitive function-

works even in the absence of APOE, which may be preferable in clinical

ing is a noninvasive, easy to use method that, in some cases, is a marker

and research settings where genetic data are not readily available.

dementias.25

Understanding that

The perceived control over future health item was included in our

SCD could be among the first clinically observable signs of AD, and in

analyses because of research suggesting a relation between the belief

some cases is not a “benign” CN state,1,28,33 it is important to deter-

that future events are under one’s own control and successful cog-

mine how to classify SCD in cognitive aging studies. Using longitudi-

nitive aging.54,65 This item made a statistically significant impact on

nal data up to 20 years of follow-up, we were able to identify a group

the incidence of aMCI in all models. There are various reasons why

of neuropsychologically intact, community-dwelling EAS participants

higher perceived control may be related to better cognition including

at increased risk of incident aMCI using baseline endorsement of self-

that such a mindset increases the motivation to adopt healthy behav-

perceived decline in cognitive functioning and other variables. We then

iors and engage in strategies that could help maintain cognitive effi-

used this information to establish cut-off scores for SCD for predicting

ciency and prevent decline.65 Also, in neuropsychologically intact older

aMCI over specified follow-up intervals.

adults, subtle cognitive changes could lead to both lower levels of per-

of risk for future aMCI, AD, or other

We began with the premise that SCD is not the same as CN and that

ceived control and a tendency to express concern about cognition,

it is important to identify the level of self-perceived cognitive decline at

which together could result in expending less effort to overcome age-

baseline that best distinguishes those at risk for future aMCI. We used

related challenges. Future research should investigate the role of per-

three approaches to handling the items probing self-perceived cogni-

ceived control in the classification and course of SCD, using items that

tive functioning that we had available: (1) a total score for all items,

inquire about control related to specific cognitive outcomes. Such an

(2) individual items that showed significant associations with incident

item may even be included on future assessments of self-perceived

aMCI, or (3) a total score that excluded items used to classify aMCI.

cognitive functioning.

In our primary approach, which used the sum of all 22 items probing

Based on the association of SCD with incident aMCI, we obtained

self-perceived cognitive functioning, results indicated that a 1-point

cut points for baseline subjective cognitive function score related to

increase in subjective cognitive function score was associated with a

developing aMCI within 3, 5, and 7 years, which optimally balanced

14% higher risk of aMCI, after controlling for relevant demographic,

sensitivity and specificity. We also provided optimal cut points using

mood, objective cognitive, and medical covariates.

the combination of SCD and other study variables based on their

When additional variables were added, the subjective cognitive

joint effect on incident aMCI (see supporting information). The AUC

function score remained significantly associated with risk of aMCI. This

results were not as high as we might have hoped. However, we are

pattern was observed for the other two approaches. Notably, in the

not proposing to use SCD as a diagnostic tool for aMCI/AD. Instead,

approach that used individual items, adjusting for demographics, of

we seek to identify a group of individuals more likely to convert to
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these conditions and, in this regard, we found statistically significant

In sum, we used available data and relevant covariates to classify

associations for SCD in terms of prediction of incident aMCI that per-

SCD in a manner that optimized the diagnostic accuracy for incident

sisted after adjusting for covariates and plus factors. In future clinical

aMCI. Based on our experience, we offer the following considera-

applications, we can imagine that SCD might be assessed as a first step,

tions:

using a self-administered questionnaire. Those who screen positive
might be offered neurocognitive or other assessments as a prelude to

1. Because we were focused on SCD related to the pre-

definitive diagnosis. Additionally, given only modest improvement in

prodromal/pre-MCI stage of AD, we did not consider progres-

accuracy when we accounted for all statistically significant covariates,

sion to naMCI, though research indicates that SCD constitutes a

for ease and simplicity, it may be advisable to set cut-off scores for SCD

heterogeneous population that in many cases remains stable or

using just the most relevant and/or readily available variables—that

progresses to non-AD etiologies.25 Researchers may need to use

is, self-perceived cognitive functioning alone or in combination with

different items or classification approaches to capture SCD that

age (in light of research suggesting that cognitive concerns may reflect

precedes non-AD dementias. Also, cut-off scores for SCD derived

different underlying changes in the young-old versus oldest-old).9,38

in the current study likely will not generalize to studies that use

In future research we will investigate the viability of our classification

other subjective cognitive items or to memory clinic samples. It is

approach through careful study and longitudinal follow-up of our SCD

important to continue with efforts to pool international data to

group. Among other things, we hope to identify specific characteristics

create a common SCD metric that can be shared across diverse

that discriminate between those with SCD due to benign conditions

studies and settings.28,66

and those in the earliest stages of neurodegenerative cognitive
decline.

2. Although we had access to a sufficient number of items probing selfperceived cognitive functioning that tapped multiple domains using

Strengths of the current study included a large, racially/ethnically

various response types and temporal referents, available items had

diverse sample with a long follow-up period. We faced several chal-

certain content and psychometric limitations, and some of the items

lenges, however, in classifying SCD in EAS participants. Although we

were used in the diagnosis of aMCI, which could result in a circular-

wanted to use AD as an outcome (in addition to aMCI), we were unable

ity issue. While there is currently no consensus on “best” items to

to do so given the relatively limited number of incident cases in our

capture SCD related to preclinical AD, overall our results suggest

sample (n = 71) and the many factors being examined, despite many

that various approaches to handling subjective cognitive data may

years of follow-up data. Additionally, we did not have biomarker evi-

yield similar results. This is positive news, as it is unlikely that inter-

dence of AD. We consider this to be a limitation, but also recognize

national aging studies will be able to arrive at a consensus on a sin-

that research that focuses on clinical features of cognition has a place

gle set of items, though research efforts should continue to refine

in the field and may be more inclusive of research participants glob-

measures and identify items with strong content and psychomet-

ally. Given significant missing data in key variables, we applied MI,

ric properties. In addition, although all individual items with associ-

which yields valid results under the assumption that data are miss-

ations to aMCI were related to memory, the scores used in models 1

ing at random (MAR), that is, the missing data process can depend on

and 3 included items tapping other cognitive domains, and all three

the observed, but not the unobserved, data. When we reran our pri-

models were roughly comparable in terms of diagnostic accuracy

mary analysis (Table S1) among those with complete subjective cogni-

for the time periods considered. Thus, results align with the sugges-

tive function data, findings were unchanged. However, this reanalysis

tion to include items that capture a diversity of cognitive domains

did not account for the high level of missingness for APOE and infor-

and other relevant features of older adults’ experiences—in a way

mant report data, which may have influenced the lack of statistically

that mirrors the heterogeneity of the SCD diagnosis itself.28,29,52,67

significant effects for these variables, despite our attempts to recover

Also, results suggest that a simple summed total of all available sub-

these data using MI. The MAR assumption is not testable without fur-

jective cognitive items might offer a practical and simple method for

ther information. In the future we will consider using a sensitivity anal-

handling these data.

ysis to explore the potential impact when data are not missing at ran-

3. Although we incorporated four SCD-plus features into our analy-

dom (MNAR). Finally, future studies would benefit from the assessment

sis (eg, concerns about memory rather than other domains, APOE

of SCD in the context of a broader set of psychological, physical, or

ε4 allele, feeling of worse performance than peers, confirmation by

behavioral characteristics (eg, anxiety, specific personality traits, med-

an informant), we did not have data for other features (eg, onset

ical help seeking, quality of life, stress, frailty) to determine their sepa-

within the past 5 years, onset at 60 years or older). Also, we had

rate and joint predictive value for subsequent MCI. Although the con-

to approximate features such as worry about overall health instead

cept of SCD was developed within a research context, increasing num-

of worry about memory, which may not capture the essence of

bers of individuals with self-perceived cognitive decline are seeking

the concern/worry that associates with an increased likelihood of

medical help and advice. Future research should determine the opti-

future AD.22 We have since added this (and other) promising items

mal SCD assessment approach for clinical settings. In addition, clini-

into the EAS battery, and we recommend continued research into

cians should be made aware of the potential significance of cognitive

the evolving SCD-plus concept, including determining whether spe-

concerns in the context of various neurocognitive, psychological, and

cific features merit incorporation into the assessment and classifi-

medical conditions.

cation process itself.
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4. The field has not yet arrived at a consensus for what constitutes
“significant” or “meaningful” concern about

cognition.28

In the cur-

rent study, we chose to focus on how subjective cognitive data
and other relevant variables impact subsequent cognitive impairment/aMCI, and we set cut points based on optimization of the
diagnostic performance using time-dependent ROC analysis. We
acknowledge that using other outcomes or approaches to “SCD
positivity” (eg, median split, 1 or 1.5 SD above the mean among cognitively healthy individuals), may have resulted in our characterizing
a different phenotype of SCD. Future research should endeavor to
explore various classification approaches using large/multisite samples with the overall goal of producing an SCD diagnosis that is stable and that predicts important clinical and cognitive outcomes.
5. Finally, the incorporation of SCD measures into clinical and
research assessments is grounded in the idea that older individuals
may be sensitive to modest, initial declines that are meaningful. This
assessment approach is useful in cross-sectional research, where
neuropsychological tests are unable to capture change in performance within the individual,1 and in longitudinal research in which
self-perceived cognitive decline is often prognostic of future cognitive impairment.21–27 However, researchers almost never provide a justification for the instruments used, methods used to score
subjective cognitive function data, or classification approach for
SCD. If the field is to advance, it is essential that researchers
report their methods as well as the rationale for their assessment
and classification choices. Without such information, it is impossible to compare findings across studies and refine the construct,
including distinguishing subgroups of individuals with SCD who are
likely on the AD/dementia trajectory, for enrichment of cohorts.
Also, in clinical trial research, classification reporting is essential
for understanding which interventions succeed and under which
conditions.
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